{"id":"https://openalex.org/W59655657","doi":null,"title":"IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.","display_name":"IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival.","alternate_titles":[],"publication_year":2005,"publication_date":"2005-06-01","ids":{"openalex":"https://openalex.org/W59655657","mag":"59655657","pmid":"https://pubmed.ncbi.nlm.nih.gov/15995632"},"language":"en","primary_location":{"id":"pmid:15995632","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15995632","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental oncology","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W59655657"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002319806","display_name":"Oleg A Kurtenkov","orcid":"https://orcid.org/0000-0003-2258-6455","observed_orcids":["https://orcid.org/0000-0003-2258-6455"]},"institutions":[{"id":"https://openalex.org/I4210145854","display_name":"National Institute for Health Development","ror":"https://ror.org/03gnehp03","country_code":"EE","type":"facility","lineage":["https://openalex.org/I4210145854"]}],"countries":["EE"],"is_corresponding":false,"raw_author_name":"O Kurtenkov","raw_affiliation_strings":["National Institute for Health Development, Tallinn 11619, Estonia. oleg.kurtenkov@tai.ee"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute for Health Development, Tallinn 11619, Estonia. oleg.kurtenkov@tai.ee","institution_ids":["https://openalex.org/I4210145854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5037660046","display_name":"Kersti Klaamas","orcid":"https://orcid.org/0000-0002-1129-9031","observed_orcids":["https://orcid.org/0000-0002-1129-9031"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Klaamas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025190195","display_name":"Kate Rittenhouse\u2010Olson","orcid":"https://orcid.org/0000-0001-8905-861X","observed_orcids":["https://orcid.org/0000-0001-8905-861X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K Rittenhouse-Olson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040458270","display_name":"Liina Vahter","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Vahter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103273274","display_name":"Boris Sergejev","orcid":"https://orcid.org/0000-0002-9431-2499","observed_orcids":["https://orcid.org/0000-0002-9431-2499"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B Sergejev","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074043679","display_name":"Ljudmila Miljukhina","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Miljukhina","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5055826510","display_name":"Ljudmila Shljapnikova","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"L Shljapnikova","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.1019,"has_fulltext":false,"cited_by_count":36,"citation_normalized_percentile":{"value":0.36082515,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"27","issue":"2","first_page":"136","last_page":"140"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10602","display_name":"Glycosylation and Glycoproteins Research","score":0.9351000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10602","display_name":"Glycosylation and Glycoproteins Research","score":0.9351000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.03840000182390213,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.004999999888241291,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/tumor-associated-carbohydrate-antigens","display_name":"tumor-associated carbohydrate antigens","score":0.9679999947547913},{"id":"https://openalex.org/keywords/t-antigen","display_name":"T antigen","score":0.5640000104904175},{"id":"https://openalex.org/keywords/tn-antigen","display_name":"Tn antigen","score":0.9959999918937683},{"id":"https://openalex.org/keywords/alpha-gal-epitope","display_name":"alpha-gal epitope","score":0.8799999952316284},{"id":"https://openalex.org/keywords/anti-carbohydrate-antibodies","display_name":"anti-carbohydrate antibodies","score":0.8140000104904175},{"id":"https://openalex.org/keywords/neoadjuvant-chemotherapy","display_name":"neoadjuvant chemotherapy","score":1.0},{"id":"https://openalex.org/keywords/cmf-chemotherapy","display_name":"CMF chemotherapy","score":0.7820000052452087},{"id":"https://openalex.org/keywords/caf-chemotherapy","display_name":"CAF chemotherapy","score":0.9710000157356262},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.7960000038146973},{"id":"https://openalex.org/keywords/cancer-survival","display_name":"cancer survival","score":0.5690000057220459},{"id":"https://openalex.org/keywords/tumor-stage","display_name":"tumor stage","score":0.6510000228881836}],"concepts":[{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6973261833190918},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.6606441736221313},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.6460171937942505},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.6205503940582275},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5681935548782349},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5536365509033203},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5264883041381836},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.5072452425956726},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.4876488447189331},{"id":"https://openalex.org/C2780252810","wikidata":"https://www.wikidata.org/wiki/Q1455316","display_name":"Immunosuppression","level":2,"score":0.47019514441490173},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.46133148670196533},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4501004219055176},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.39028337597846985},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3550523817539215},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3210408091545105}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000519","descriptor_name":"alpha-Galactosidase","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000912","descriptor_name":"Antibodies, Neoplasm","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":true},{"descriptor_ui":"D000917","descriptor_name":"Antibody Formation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000939","descriptor_name":"Epitopes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":true},{"descriptor_ui":"D003520","descriptor_name":"Cyclophosphamide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D004317","descriptor_name":"Doxorubicin","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006241","descriptor_name":"Haptens","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008727","descriptor_name":"Methotrexate","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013925","descriptor_name":"Thromboplastin","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015295","descriptor_name":"Antigens, Tumor-Associated, Carbohydrate","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018226","descriptor_name":"Fibroadenoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D018226","descriptor_name":"Fibroadenoma","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D018226","descriptor_name":"Fibroadenoma","qualifier_ui":"Q000401","qualifier_name":"mortality","is_major_topic":false},{"descriptor_ui":"D020360","descriptor_name":"Neoadjuvant Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:15995632","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15995632","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Experimental oncology","raw_type":"Journal Article"},{"id":"mag:59655657","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15995632","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2494777024","https://openalex.org/W1520231470","https://openalex.org/W4256679107","https://openalex.org/W1977314595","https://openalex.org/W2028154780","https://openalex.org/W1983038458","https://openalex.org/W2072961453","https://openalex.org/W2120888343","https://openalex.org/W2805915954","https://openalex.org/W2012736595"],"abstract_inverted_index":{"AIM:":[0],"To":[1],"study":[2],"the":[3,23,27,33,46,72,125,131,168,249,283,295],"humoral":[4,55],"immune":[5,56,165,250],"response":[6,57,166,251],"to":[7,30,37,58,167,187,252],"tumor-associated":[8,253],"carbohydrate":[9,108,254],"epitopes":[10,39,142,191,255],"(TF,":[11],"Tn":[12,60,188],"and":[13,20,29,61,81,97,102,130,140,189],"alphaGal)":[14],"in":[15,65,98,115,143,195,203,209,256],"patients":[16,47,67,73,86,93,103],"with":[17,48,68,104,159,224,269],"breast":[18,49,69,232,276],"cancer":[19,233,277],"healthy":[21],"donors,":[22],"putative":[24],"impact":[25],"of":[26,35,127,133,138,153,173,180,199,211,215,229,240,262,273,285,288],"chemotherapy":[28,84,90,183,242,290],"evaluate":[31],"if":[32],"level":[34,126,152],"antibody":[36,119,185,204,219,264],"these":[38],"might":[40,291],"be":[41,292],"beneficial":[42,293],"or":[43],"detrimental":[44],"for":[45,117,294],"cancer.":[50,181],"MATERIALS":[51],"AND":[52],"METHODS:":[53],"The":[54,121,151,236,259],"TF,":[59],"alphaGal":[62,141,190],"was":[63,148,206],"studied":[64],"133":[66],"cancer,":[70,134],"including":[71],"at":[74,177],"stage":[75,132,230,274],"II-III":[76],"(n":[77],"=":[78],"44)":[79],"before":[80,220,265],"after":[82],"neoadjuvant":[83,241,289],"(10":[85],"received":[87,94],"cyclophosphamide/methotrexate/fluorouracyl":[88],"(CMF)":[89],"regimens,":[91],"34":[92],"cyclophosphamide/doxorubicin/fluorouracil":[95],"(CAF)),":[96],"controls":[99],"(healthy":[100],"donors":[101],"fibroadenoma).":[105],"Fully":[106],"synthetic":[107],"hapten-polyacrylamide":[109],"conjugates":[110],"were":[111,175,222],"used":[112,238],"as":[113,244],"antigens":[114],"ELISA":[116],"anti-carbohydrate":[118,128,154],"determination.":[120],"correlation":[122,162],"analysis":[123],"between":[124,157,163],"antibodies":[129,155,174],"histological":[135],"grade,":[136],"expression":[137],"TF":[139],"tumor":[144],"tissue,":[145],"patient's":[146],"survival":[147,227,272],"performed.":[149],"RESULTS:":[150],"varied":[156],"individuals":[158],"no":[160],"significant":[161],"IgG":[164,218],"three":[169],"epitopes.":[170],"Lower":[171],"levels":[172,214,261],"observed":[176,207],"advanced":[178],"stages":[179],"Neoadjuvant":[182],"stimulated":[184],"production":[186],"(increase":[192],">":[193],"50%)":[194],"about":[196],"one":[197],"third":[198],"patients.":[200,234,258,278],"Immunosuppression,":[201],"decrease":[202],"levels,":[205],"only":[208],"4.5-13.6%":[210],"cases.":[212],"High":[213],"TF-antigen":[216],"specific":[217],"surgery":[221,266],"associated":[223,268],"a":[225,270],"better":[226,271],"time":[228],"II":[231,275],"CONCLUSION:":[235],"widely":[237],"regimens":[239,287],"(such":[243],"CMF,":[245],"CAF)":[246],"can":[247],"stimulate":[248],"some":[257],"high":[260],"anti-TF":[263],"are":[267],"This":[279],"may":[280],"indicate":[281],"that":[282],"selection":[284],"immunopotentiating":[286],"host.":[296]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W59655657","counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
